Sponsor - Genentech (Open to Enrollment)
GALLEGO
A PHASE
II, MULTICENTER, RANDOMIZED, SINGLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS
SAFETY, TOLERABILITY, AND EFFICACY OF INTRAVITREAL INJECTIONS OF FHTR2163 IN
PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
(GALLEGO)
https://clinicaltrials.gov/ct2/show/NCT03972709?term=gallego&rank=1
Sponsor - Ionis (Open to Enrollment)
ISIS
A Phase 2,
Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and
Efficacy of Multiple Doses of IONIS-FB-Lrx, an Antisense Inhibitor of
Complement Factor B, in Patients with Geographic Atrophy Secondary to
Age-Related Macular Degeneration (AMD)
https://clinicaltrials.gov/ct2/show/NCT03815825?term=isis+696844&rank=1
Sponsor - Stealth BioTherapeutics (Open to Enrollment)
SPIAM-202
APhase 2,
Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the
Safety, Efficacy, and Pharmacokinetics of Subcutaneous Injections of
Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic
Atrophy
https://clinicaltrials.gov/ct2/show/NCT03891875?term=spiam&rank=1
Sponsor - Apellis (Recruitment/Not Yet Open)
OAKS
A Phase III,
Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the
Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in
Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular
Degeneration (AMD)
Sponsor - Allergan (Recruitment/Not Yet Open)
IMAGINE
Efficacy
and Safety of Brimonidine Drug Delivery System (Brimo DDS
®) in
Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration:
A Phase III Randomized, Double-masked, Sham Procedure-controlled Trial
Previous Dry AMD Studies:
Principal Investigator, 2016 - 2017
Sponsor: Genentech/Roche
Study: OMASPECT
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A ROCHE-SPONSORED STUDY
https://clinicaltrials.gov/ct2/show/NCT02745119?term=OMASPECT&rank=1
Principal Investigator, 2014 - 2017
Sponsor: Genentech/Roche
Study: CHROMA – Geographic Atrophy (GA)
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
https://clinicaltrials.gov/ct2/results?term=CHROMA&Search=Search